1. Emerging   Therapies for Psoriatic Arthritis: Perspectives From Washington, DC  

2. Part 1: Disease Activity Measures

3. Part 2: Safety in PsA

4. Part 3: JAK-STAT Pathway in PsA

5. Part 4: Core Domains in PsA

6. Of Note

7. Disease Assessment in Psoriatic Arthritis

8. TICOPA Trial Background

9. Methods

10. Findings

11. Conclusions

12. PASDAS vs MDA Study Background

13. Findings

14. Conclusions

15. Safety in Psoriatic Arthritis

16. Statin Use Study Background

17. Methods

18. Findings

19. Conclusions

20. PSOLAR Study Background

21. Findings

22. Findings (cont)

23. Caveats

24. Conclusions

25. JAK-STAT Pathway Inhibition in Psoriatic Arthritis

26. The IL-23/IL-17 Cytokine Axis

27. In Vitro Study of JAK/STAT Signaling

28. Findings of In Vitro Tofacitinib Study

29. Conclusions Drawn From Study Findings

30. Phase 3 Tofacitinib Trials: Study Design

31. OPAL Beyond: Results

32. Mease et al Trial: Results

33. Conclusions of Both Tofacitinib Trials

34. Core Domains and Psoriatic Arthritis

35. PsA Core Domains Study Background

36. Methods

37. Findings

38. Endorsed at OMERACT 2016

39. Conclusions

40. Abbreviations

41. Abbreviations (cont)

42. Abbreviations (cont)